12 Aug 2024 Research & Development Spotlight Series – Episode 4 Blogs | Podcasts and Videos | R&D Spotlights Series | Therapeutics
03 Jun 2024 Research & Development Spotlight Series – Episode 3 Blogs | Investors | Podcasts and Videos | R&D Spotlights Series | Therapeutics
23 May 2024 Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta’s AVA6000 Phase 1 trial Investors | Therapeutics
25 Apr 2024 Research and Development Spotlight Series – Episode 2 Blogs | Investors | Podcasts and Videos | R&D Spotlights Series | Therapeutics
09 Apr 2024 Christina Coughlin – AACR 2024 – AVA6000 data presentation Blogs | Investors | Podcasts and Videos | Therapeutics
09 Apr 2024 Avacta Therapeutics Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 at the AACR Annual Meeting Demonstrating Clinical Proof-of-Concept Showing Multiple Patient Responses Investors | Therapeutics
27 Mar 2024 Research and Development Spotlight Series – Episode 1 Blogs | Investors | Podcasts and Videos | R&D Spotlights Series | Therapeutics
06 Mar 2024 Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9, 2024 Therapeutics